External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>GLAND has 11 injectable products in the USFDA shortage list, which have combined sales of ~USD400m over the past 12-months.</li><li>The overall number of drugs under shortage in the US has declined to a 15-year low at present.</li><li>However, the number of injectables facing a shortage is at its 20-year average, but is at a record high as a percentage of total drug shortages.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

GLAND has 11 injectable products in the USFDA shortage list, which have combined sales of ~USD400m over the past 12-months.The overall number of drugs under shortage in the US has declined to a 15-year low at present.However, the number of injectables facing a shortage is at its 20-year average, but is at a record high as a percentage of total drug shortages.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Gland Pharma: Well-Placed to Gain from the Drug Shortages in the US

Gland Pharma Ltd

Gland Pharma: Well-Placed to Gain from the Drug Shortages in the US